Evogene Ltd reports results for the quarter ended June 30 - Earnings Summary

• Evogene Ltd EVGN reported a quarterly adjusted loss of 62 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.06. The mean expectation of two analysts for the quarter was for a loss of 63 cents per share. Wall Street expected results to range from -65 cents to -61 cents per share.

• Revenue fell 3.3% to $884.00 thousand from a year ago; analysts expected $930.00 thousand.

• Evogene Ltd's reported EPS for the quarter was a loss of 62 cents​.

• The company reported a quarterly loss of $4.46 million.

• Evogene Ltd shares had risen by 3.6% this quarter and lost 29.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 0.8% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Evogene Ltd is $3.50, about 62.1% above its last closing price of $1.33

This summary was machine generated from LSEG data August 19 at 01:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)